{"id":12226,"date":"2021-05-18T17:29:09","date_gmt":"2021-05-18T11:59:09","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=12226"},"modified":"2021-07-24T12:58:22","modified_gmt":"2021-07-24T07:28:22","slug":"pharma-happening-for-sanofi-gsk-apellis-innocare-landos","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happening-for-sanofi-gsk-apellis-innocare-landos","title":{"rendered":"InnoCare&#8217;s Trial In China; Sanofi\/GSK COVID-19 Vaccine; Apellis\u2019s Empaveli for PNH; LianBio, Landos Collab"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fe4f244a1c7\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fe4f244a1c7\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happening-for-sanofi-gsk-apellis-innocare-landos\/#InnoCare_Receives_Go-ahead_for_Clinical_Trial_of_TYK2_Inhibitor_ICP-332_in_China\" >InnoCare Receives Go-ahead for Clinical Trial of TYK2 Inhibitor ICP-332 in China<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happening-for-sanofi-gsk-apellis-innocare-landos\/#SanofiGSK_COVID-19_Vaccine_Phase_II_Trial_Reports_Positive_Results\" >Sanofi\/GSK COVID-19 Vaccine Phase II Trial Reports Positive Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happening-for-sanofi-gsk-apellis-innocare-landos\/#FDA_Approval_to_Apelliss_Empaveli_for_Paroxysmal_Nocturnal_Hemoglobinuria\" >FDA Approval to Apellis\u2019s Empaveli for Paroxysmal Nocturnal Hemoglobinuria<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happening-for-sanofi-gsk-apellis-innocare-landos\/#LianBio_Landos_Teams_Up_to_Commercialize_Colitis_Crohns_Treatments_in_China\" >LianBio, Landos Teams Up to Commercialize Colitis, Crohn\u2019s Treatments in China<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-innocare-receives-go-ahead-for-clinical-trial-of-tyk2-inhibitor-icp-332-in-china\"><span class=\"ez-toc-section\" id=\"InnoCare_Receives_Go-ahead_for_Clinical_Trial_of_TYK2_Inhibitor_ICP-332_in_China\"><\/span><strong>InnoCare Receives Go-ahead for Clinical Trial of TYK2 Inhibitor ICP-332 in China<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>InnoCare, a biopharma firm developing novel therapies for the treatment of cancer and autoimmune diseases, today announced the approval of Phase I clinical trial of its novel TYK2 (Tyrosine Kinase 2) inhibitor, <strong>ICP-332<\/strong>, by the China National Medical Products Administration.<\/p>\n\n\n\n<p>TYK2 (Tyrosine Kinase 2) inhibitor is a member of the JAK kinase family, which is an important kinase on the JAK-STAT signaling pathway, playing an important role in the pathogenesis of <a href=\"https:\/\/www.delveinsight.com\/blog\/chronic-pain-pipeline\/?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">inflammatory diseases<\/a>.&nbsp;<\/p>\n\n\n\n<p>The company developed oral ICP-332, a potent and selective TYK2 inhibitor with 400 folds of selectivity against JAK2 to prevent the adverse events associated with non-selective JAK inhibitors. At present, there is no selective TYK2 inhibitor in the pharma market and if approved, the drug will help lower down the burden due to autoimmune diseases such as psoriasis and atopic dermatitis.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-sanofi-gsk-covid-19-vaccine-phase-ii-trial-reports-positive-results\"><span class=\"ez-toc-section\" id=\"SanofiGSK_COVID-19_Vaccine_Phase_II_Trial_Reports_Positive_Results\"><\/span><strong>Sanofi\/GSK COVID-19 Vaccine Phase II Trial Reports Positive Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Sanofi and GSK have been leveraging the traditional approach when it comes to the development of vaccines for COVID-19. Earlier, the decision looked a bit unfruitful owing to delays due to failure in demonstrating effectiveness in older individuals.&nbsp;<\/p>\n\n\n\n<p>However, it looks like there is still hope. The duo presented the results from the Phase II trials of 722 volunteers investigating their <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-coronavirus-pipeline-insights?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">COVID-19 vaccine candidate<\/a> in all adult age groups. The Phase II interim data demonstrated 95% to 100% seroconversion after the second injection in all age groups, ranging from 18 to 95. There were no safety concerns, and tolerability was acceptable. Moreover, the vaccine provided strong neutralizing antibody levels similar to that in people who recovered from COVID-19, with higher levels in younger adults ages 18 to 59.<\/p>\n\n\n\n<p>The duo, although, failed to have an early-mover advantage as its rivals such as Pfizer-BioNTech, Moderna, AstraZeneca-Oxford, and Johnson &amp; Johnson are distributing their doses on a large scale in several western markets, however, the demand is clearly exceeding the supply, there is still a place for Sanofi\/GSK COVID-19 vaccine in the market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approval-to-apellis-s-empaveli-for-paroxysmal-nocturnal-hemoglobinuria\"><span class=\"ez-toc-section\" id=\"FDA_Approval_to_Apelliss_Empaveli_for_Paroxysmal_Nocturnal_Hemoglobinuria\"><\/span><strong>FDA Approval to Apellis\u2019s Empaveli for Paroxysmal Nocturnal Hemoglobinuria<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Apellis recently announced the U.S. FDA approval to its drug, <strong>Empaveli, <\/strong>for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/paroxysmal-hemoglobinuria-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">paroxysmal nocturnal hemoglobinuria<\/a> (PNH).<\/p>\n\n\n\n<p>Empaveli (pegcetacoplan) is the first and only targeted C3 therapy for the treatment of adults with PNH and is approved for use in PNH patients who are treatment na\u00efve as well as patients switching from the C5 inhibitors Soliris (eculizumab) and Ultomiris (ravulizumab). The approval was based on the results from the Phase III <strong>PEGASUS <\/strong>study.&nbsp;<\/p>\n\n\n\n<p>As per DelveInsiht\u2019s PNH epidemiological analysis, the diagnosed prevalence in 2020 was 8,385 in the 7MM (the US, EU5 and Japan), out of which the USA accounted for maximum cases. At present, the only disease-modifying therapeutic strategies for PNH are complement inhibition therapy (eculizumab and ravulizumab) and bone marrow transplantation; however, the approval of Empaveli marks a significant step ahead in the first new class of complementary medicine in almost 15 years. Other companies working in the PNH market include Hoffmann-La Roche, Novartis, Alexion Pharmaceutical, Regeneron Pharmaceuticals, RA Pharmaceuticals, and others.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-lianbio-landos-teams-up-to-commercialize-colitis-crohn-s-treatments-in-china\"><span class=\"ez-toc-section\" id=\"LianBio_Landos_Teams_Up_to_Commercialize_Colitis_Crohns_Treatments_in_China\"><\/span><strong>LianBio, Landos Teams Up to Commercialize Colitis, Crohn\u2019s Treatments in China<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>US-based Landos Biopharma announced a partnership with China-based LianBio to manufacture and market <strong>omilancor <\/strong>and <strong>NX-13 <\/strong>in Greater China and select Asian markets.&nbsp;<\/p>\n\n\n\n<p><strong>Omilancor <\/strong>is an oral, gut-restrict LANCL2 agonist under development for <a href=\"https:\/\/www.delveinsight.com\/report-store\/ulcerative-colitis-uc-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">Ulcerative Colitis <\/a>(UC), Crohn\u2019s disease (CD), and <a href=\"https:\/\/www.delveinsight.com\/report-store\/eosinophilic-esophagitis-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">Eosinophilic Esophagitis<\/a> (EoE). Similarly, <strong>NX-13 <\/strong>is an oral, gut-restricted compound that targets NLRX1 and is being developed for UC and <a href=\"https:\/\/www.delveinsight.com\/report-store\/crohns-disease-cd-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">CD<\/a>.<\/p>\n\n\n\n<p>As per the terms of the agreement, LianBio will have exclusive rights to develop and commercialize omilancor and NX-13 in Greater China, South Korea, Singapore, Thailand, Vietnam, Myanmar, Cambodia, Indonesia, and the Philippines; while paying Landos upfront cash of&nbsp; $18 million and up to $200 million in various development and commercial milestones, and tiered low double-digit royalties on net sales in the select areas.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>InnoCare Receives Go-ahead for Clinical Trial of TYK2 Inhibitor ICP-332 in China InnoCare, a biopharma firm developing novel therapies for the treatment of cancer and autoimmune diseases, today announced the approval of Phase I clinical trial of its novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332, by the China National Medical Products Administration. TYK2 (Tyrosine Kinase [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":12230,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[99,15648,2077,17001,2699,17000,16410],"industry":[17225],"therapeutic_areas":[17239,17233,17228,17234,17243],"class_list":["post-12226","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-autoimmune-disorders","tag-covid-19-vaccines","tag-crohns-disease","tag-eosinophilic-esophagitis","tag-paroxysmal-nocturnal-hemoglobinuria","tag-pnh","tag-ulcerative-colitis","industry-pharmaceutical","therapeutic_areas-gastroenterology","therapeutic_areas-hematological-disorders","therapeutic_areas-oncology","therapeutic_areas-rare-diseases","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Sanofi\/GSK COVID Vaccine; Apellis in PNH market; LianBio\/Landos Collab<\/title>\n<meta name=\"description\" content=\"InnoCare&#039;s Trial In China; Sanofi\/GSK COVID-19 Vaccine; Apellis\u2019s Empaveli for PNH; LianBio, Landos Collaboration\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happening-for-sanofi-gsk-apellis-innocare-landos\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi\/GSK COVID Vaccine; Apellis in PNH market; LianBio\/Landos Collab\" \/>\n<meta property=\"og:description\" content=\"InnoCare&#039;s Trial In China; Sanofi\/GSK COVID-19 Vaccine; Apellis\u2019s Empaveli for PNH; LianBio, Landos Collaboration\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happening-for-sanofi-gsk-apellis-innocare-landos\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-18T11:59:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/05\/18172711\/recent-pharma-biotech-news-updates-for-sanofi-gsk-apellis-innocare-landos.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"773\" \/>\n\t<meta property=\"og:image:height\" content=\"483\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi\/GSK COVID Vaccine; Apellis in PNH market; LianBio\/Landos Collab","description":"InnoCare's Trial In China; Sanofi\/GSK COVID-19 Vaccine; Apellis\u2019s Empaveli for PNH; LianBio, Landos Collaboration","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happening-for-sanofi-gsk-apellis-innocare-landos","og_locale":"en_US","og_type":"article","og_title":"Sanofi\/GSK COVID Vaccine; Apellis in PNH market; LianBio\/Landos Collab","og_description":"InnoCare's Trial In China; Sanofi\/GSK COVID-19 Vaccine; Apellis\u2019s Empaveli for PNH; LianBio, Landos Collaboration","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happening-for-sanofi-gsk-apellis-innocare-landos","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-05-18T11:59:09+00:00","article_modified_time":"2021-07-24T07:28:22+00:00","og_image":[{"width":773,"height":483,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/05\/18172711\/recent-pharma-biotech-news-updates-for-sanofi-gsk-apellis-innocare-landos.jpg","type":"image\/jpeg"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happening-for-sanofi-gsk-apellis-innocare-landos","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happening-for-sanofi-gsk-apellis-innocare-landos","name":"Sanofi\/GSK COVID Vaccine; Apellis in PNH market; LianBio\/Landos Collab","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happening-for-sanofi-gsk-apellis-innocare-landos#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happening-for-sanofi-gsk-apellis-innocare-landos#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/05\/18172711\/recent-pharma-biotech-news-updates-for-sanofi-gsk-apellis-innocare-landos.jpg","datePublished":"2021-05-18T11:59:09+00:00","dateModified":"2021-07-24T07:28:22+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"InnoCare's Trial In China; Sanofi\/GSK COVID-19 Vaccine; Apellis\u2019s Empaveli for PNH; LianBio, Landos Collaboration","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happening-for-sanofi-gsk-apellis-innocare-landos"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happening-for-sanofi-gsk-apellis-innocare-landos#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/05\/18172711\/recent-pharma-biotech-news-updates-for-sanofi-gsk-apellis-innocare-landos.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/05\/18172711\/recent-pharma-biotech-news-updates-for-sanofi-gsk-apellis-innocare-landos.jpg","width":773,"height":483,"caption":"recent-pharma-biotech-news-updates-for-sanofi-gsk-apellis-innocare-landos"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/05\/18172711\/recent-pharma-biotech-news-updates-for-sanofi-gsk-apellis-innocare-landos-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Autoimmune disorders<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Covid-19 vaccines<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Crohn\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eosinophilic Esophagitis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Paroxysmal Nocturnal Hemoglobinuria<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">PNH<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ulcerative colitis<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Autoimmune disorders<\/span>","<span class=\"advgb-post-tax-term\">Covid-19 vaccines<\/span>","<span class=\"advgb-post-tax-term\">Crohn\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">Eosinophilic Esophagitis<\/span>","<span class=\"advgb-post-tax-term\">Paroxysmal Nocturnal Hemoglobinuria<\/span>","<span class=\"advgb-post-tax-term\">PNH<\/span>","<span class=\"advgb-post-tax-term\">Ulcerative colitis<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on May 18, 2021","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on May 18, 2021 5:29 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"recent-pharma-biotech-news-updates-for-sanofi-gsk-apellis-innocare-landos","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=12226"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12226\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/12230"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=12226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=12226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=12226"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=12226"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=12226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}